ABOUT CAMURUS
Delivering better treatments
Camurus is a research based pharmaceutical company with a firm commitment to the development and commercialization of innovative specialty medicines, providing patients suffering from serious and chronic disease, with better treatment outcomes and quality of life.
Press releases
- 2021-02-11 Camurus’ Full Year...
- 2021-01-29 Change in number of...
- 2021-01-04 Camurus appoints Andrew...
PRODUCT PIPELINE
Breakthrough for our products and technologies
Camurus is a research based pharmaceutical company with a firm commitment to the development and commercialization of innovative specialty medicines, providing patients…
Events
- 2020-03-02 Cowen and Co. Annual...
- 2020-03-04 Carnegie Health Care...
- 2020-03-23 BIO-Europe Spring
Total costs to society of opiod abuse in the US in 2007
Problem users in Europe
Opiod dependent people globally
Opiod abusers in the US
INVESTOR RELATIONS
Establishment of marketing organisation in Europe
Welcome to the investor relations section. Our ambition is to update shareholders and other parties on the capital market about Camurus status and performance on regular basis.
If you have questions please contact us.
A product with the potential to become a game-changer in the treatment
Fredrik Tiberg
TECHNOLOGIES
Breakthrough for our products and technologies
Camurus is a research based pharmaceutical company with a firm commitment to the development and commercialization of innovative specialty medicines, providing patients suffering from serious and chronic disease, with better treatment outcomes and quality of life.
Camurus AB
Ideon Science Park. SE-223 70 Lund, Sweden.
Visiting address
Sölvegatan 41 A. 223 62 Lund, Sweden.
Phone: +46 46 286 57 30
Fax: +46 46 286 57 39
Email Addresses
General enquiries: info@camurus.com
Business Development: busdev@camurus.com
Media: media@camurus.com
Investor Relations ir@camurus.com